Heart Biomarker Evaluation in Apnea Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

August 31, 2012

Conditions
Cardiovascular DiseaseObstructive Sleep ApneaCoronary Artery Disease
Interventions
OTHER

Healthy Lifestyles and Sleep Education plus PAP

Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.

OTHER

Healthy Lifestyles and Sleep Education plus Supplemental Oxygen

Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.

OTHER

Healthy Lifestyles and Sleep Education

Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.

Trial Locations (4)

21224

Johns Hopkins University, Baltimore

44106

Case Western Reserve University, Cleveland

02115

Partners HealthCare, Boston

02132

VA Boston Healthcare System, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

collaborator

Partners HealthCare

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

VA Boston Healthcare System

FED

lead

Brigham and Women's Hospital

OTHER

NCT01086800 - Heart Biomarker Evaluation in Apnea Treatment | Biotech Hunter | Biotech Hunter